Healthcare
Advancements in EGFR-Targeted Therapies: Promising Phase 1b Data for Firmonertinib in NSCLC Patients with Rare EGFR Mutations
Novel treatments show potential in addressing hard-to-treat mutations in lung cancer, bringing hope for improved outcomes ArriVent Biopharma recently unveiled...
Summit Therapeutics Announces Promising Phase III Trial Results for Ivonescimab in Lung Cancer
First-line treatment shows significant improvement in progression-free survival over pembrolizumab, marking a potential shift in NSCLC care Summit Therapeutics (SMMT)...
SYRE’s Innovative Biologics: A Game-Changer in Inflammatory Bowel Disease Treatment
Targeting Leading IBD Pathways, SYRE Aims to Redefine Efficacy and Convenience with Next-Generation Antibodies SYRE (SYRE), a clinical-stage biopharmaceutical company,...
Eli Lilly Introduces Affordable Version of Zepbound to Address Soaring Demand and Combat Counterfeit Drugs
New Single-Dose Vials of Zepbound Priced at Half the Cost Aim to Increase Access for Uninsured Patients Eli Lilly (LLY)...
Conduit Pharmaceuticals Secures Exclusive Licensing Agreement with AstraZeneca for Novel Therapeutics
Phase II Trials Set to Begin on Glucokinase Activators and Myeloperoxidase Inhibitor Targeting Autoimmune Disorders and Male Infertility Conduit Pharmaceuticals...
Corbus Pharmaceuticals: Pioneering Next-Generation Therapies in Cancer and Obesity
Revolutionary Treatments on the Horizon with CRB-701 and CRB-913 Corbus Pharmaceutical (CRPB), an early-stage clinical biotechnology company, is making significant...
TARS Pharmaceuticals: XDEMVY Eye Drops Set for Strong Performance in 2Q24 Amid Strategic Sales Expansion
Anticipated Growth in XDEMVY Sales, Sales Force Expansion, and Promising Pipeline Signal a Bright Future for TARS Pharmaceuticals As we...
Why Are These Stocks Surging Today?
Examining the Unprecedented Moves of Windtree Therapeutics, Regencell Therapeutics, and Coursera In the ever-fluctuating stock market, certain companies stand out...
Viking Therapeutics Advances Multiple Therapies Amid Strong Clinical Progress and Financial Stability
Obesity Drug VK2735 to Enter Phase 3, NASH Therapy VK2809 Shows Promising Results, and Novel Treatments in Development Viking Therapeutics...
Breakthrough in Hemophilia A Treatment: Pfizer’s Gene Therapy Shows Promising Results
AFFINE Study Demonstrates Superiority of Giroctocogene Fitelparvovec Over Routine Prophylaxis Pfizer (PFE) recently announced encouraging results from the Phase 3...
